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http://dx.doi.org/10.1016/j.pedneo.2Despite theexistenceof a government-run tuberculosis (TB) control program, the current nation-
wide burden of TB continues to be a public health problem in Taiwan. Intense current and previ-
ous efforts into diagnostic, therapeutic, and preventive interventions have focused on TB in
adults, but childhood TB has been relatively neglected. Children are particularly vulnerable to
severe disease and death following infection, and children with latent infections become reser-
voirs for future transmission following disease reactivation in adulthood, thus fueling future ep-
idemics. Additional research, understanding, and prevention of childhood TB are urgently
needed. This review assesses the epidemiology, diagnosis, treatment, and relevant principles
of TB vaccine development and presents efficacy data for the currently licensed vaccines.
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Table 1 Proportion of childhood tuberculosis (TB) cases
among all TB cases and annual incidence of TB in children
and adults in Taiwan, 2002e2009.
Year Total no. of
cases*




2002 18,013 223 (1.24) 4.82 99.76
2003 14,074 122 (0.87) 2.69 77.41
2004 17,142 140 (0.82) 3.16 93.50
2005 16,472 118 (0.72) 2.73 88.85
2006 15,378 114 (0.74) 2.71 81.97
2007 14,480 115 (0.79) 2.81 76.29
2008 14,265 112 (0.79) 2.82 74.37
2009 13,336 100 (0.75) 2.60 68.80
Total 123,160 1044 (0.85) 3.04 82.60
* Includes the number of cases in children and adults.
y Expressed by cases per 100,000/year.
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Tuberculosis (TB) is prevalent in poor and marginalized
populations, although human immunodeficiency virus (HIV)
infection is another major driver of the epidemic in certain
areas.1 Poor case ascertainment and limited surveillance
data hamper the efforts to accurately quantify the disease
burden associated with childhood TB.2 Childhood TB con-
tributes approximately 15e40% of all TB cases.3e5 Childhood
TB is usually acquired from an infectious adult contact. High
rates of transmission are sustained in TB-endemic areas due
to high case density and prolonged diagnostic delay.6 As
childhood TB reflects ongoing transmission, children are
affectedmost acutely in areas where an adult TB epidemic is
poorly controlled.7 The global TB control strategy has
focused predominantly on smear-positive cases and, there-
fore, not on childhood TB,which is usually paucibacillary and
smear negative.3 In addition, childhood TB remains neglec-
ted for various reasons, mainly the difficulty in diagnosing
pulmonary TB, the lack of scientific studies on childhood TB,
the largely unknown outcomes of children with TB, and the
belief that childhood TB is not important for TB control.3,8
Although nearly 11% of all global TB cases occur in children
less than 15 years of age,7 childhood TB is not prioritized by
national control programs because children contribute little
to transmission. Moreover, children in TB-endemic areas
suffer severe TB-relatedmorbidity andmortality, and a large
proportion of cases are diagnosed solely on the basis of
medical history and clinical examination.2,3 Further
research, understanding, and prevention of TB among chil-
dren are urgently needed. The purpose of this review is to
explore the epidemiology, diagnosis, treatment, and rele-
vant principles of TB vaccine development and to present
efficacy data for the currently licensed vaccines.
2. Epidemiology
2.1. Global childhood TB
The World Health Organization (WHO) estimates that of
the approximately 8.3 million new cases of TB diagnosed
in 2000, 10% were children less than 15 years of age.3
During 2008, an estimated 9.4 million new TB cases were
diagnosed, with most cases living in Africa and Asia,1 but
no estimates of childhood TB were included. In a pro-
spective community-based survey performed in an area of
South Africa, children less than 13 years of age con-
tributed 14% of the total TB disease burden, with an
annual incidence of 408/100,000.9 More recent estimates
suggest that children less than 15 years of age contribute
10e20% of the disease burden in TB-endemic areas.10
From these informal observations, it is evident that chil-
dren with TB are frequently misdiagnosed in TB-endemic
areas, and we are currently only witnessing a small
piece of the overall picture with the bulk of cases passing
undetected. The misperception that children with TB
rarely develop serious disease was based on data from
developed countries where diligent contact tracing and
active case finding ensure that children are diagnosed
early in their disease course. By contrast, children in
developing countries have a 20-fold greater risk for TBdisease than HIV-uninfected children and are at much
higher risk of TB-related death.11
2.2. Childhood TB in Taiwan
We analyzed data obtained from the Taiwan Tuberculosis
Control Report, which was published by the Center for
Disease Control (Taiwan CDC).12 The data indicated that
the proportion of childhood TB among all TB cases ranged
between 0.72% and 1.24% during the data collection period
(2002 and 2009) (Table 1). The number of childhood TB
cases detected each year was relatively small. The overall
annual incidence rate during the entire data collection
period was 3.04 and 82.60 per 100,000 population for
children and adults, respectively. For children, there was
a 46% decrease in the incidence of TB, a decrease from
4.82/100,000 population in 2002 to 2.60/100,000 popula-
tion in 2009 (Chi-square test for the linear trend Z 19.3,
p < 0.001). For adults, the incidence of TB decreased 31%
during the study period from 99.76/100,000 population in
2002 to 68.80/100,000 population in 2009 (Chi-square test
for the linear trend Z 5.8, p Z 0.016) (Table 1).
The annual incidence by age group presented a decline in
the most recent years, demonstrating a peak incidence rate
in the 10e14 year age group (3.63 per 100,000 population),
followed by the 0e4 year age group (3.18 per 100,000), and
the 5e9 year age group (2.27 per 100,000) (Figure 1A).
Overall, childhood TB incidences in all age groups were
highest in 2002 and decreased in the following years.
The annual incidence rates by gender are shown in
Figure 1B. Females had higher incidence rate thanmales (3.18
vs. 2.91per100,000population;Chi-squareZ3.96,pZ0.03).
The childhood incidence rate by region is shown in
Figure 2. The incidence patternwas different among the four
regions studied between 2002 and 2009. The eastern region
had the highest rate of all of the studied regions (16.2 per
100,000), followed by the southern region (3.00/100,000),
the northern region (2.39/100,000), and the central region
(1.93/100,000). The adult incidence rate by region was as
follows: the eastern region (127.24 per 100,000), the
southern region (88.50/100,000), the central region (72.56/
100,000), and the northern region (64.37/100,000).
Figure 1 Annual incidence of tuberculosis (TB) in children under 15 years old by age group (A) and gender (B) in Taiwan,
2002e2009.
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Diagnostic difficulties pose the greatest challenge to
childhood TB management. TB can mimic many common
childhood diseases, including pneumonia, generalized
bacterial and viral infections, malnutrition, and HIV infec-
tion. However, the main impediment to the accurate
diagnosis of active TB is the paucibacillary nature of the
disease in children.13 Younger children also produce smaller
amounts of sputum, which is usually swallowed rather than
expectorated. Consequently, bacteriological confirmation
is the exception rather than the rule, with only 10e15% of
sputum samples revealing acid-fast bacilli (AFB) and spu-
tum cultures remaining negative in approximately 70% of
cases with probable TB.14 The diagnosis of TB is usuallybased on exposure history, clinical features, tuberculin skin
test (TST), and chest radiography.15,16
3.1. Clinical features of disease
Fever and/or cough of recent onset lasting longer than 2
weeks should arouse suspicion of TB.17 Fever can be of any
type, and the often-described evening rise of temperature
is neither specific to this etiology nor commonly present.
The cough can be dry or moist and may be severe. A cough
persisting beyond 2 weeks, particularly as the only symp-
tom in an otherwise healthy child, can be due to asthma
and is often not due to TB. A recent loss of appetite may be
relevant, but the unexplained recent loss of weight can be
an important symptom suggesting TB. A history of contact
Figure 2 Annual incidence of tuberculosis by region in Taiwan, 2002e2009: (A) in children under 15 years old; (B) in adults.
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a detailed examination for the disease. Persistent lower
respiratory infection that is not responsive to antibiotic
therapy may indicate a probable TB diagnosis. Significant
superficial lymphadenopathy should be specifically sought,
as it often coexists with TB infection.
3.2. Tuberculin skin test
The Mantoux test is the recommended standard tuberculin
test.18 Tuberculin is commercially available in 1, 2, and 5
Tuberculin Unit (TU) PPD (purified protein derivative, RT23
equivalent) forms.19,20 For the test, it is important to raise
a wheal of approximately 6 mm after the intradermal in-
jection. The test is read 48e72 hours after an injection.
Ballpoint or palpatory methods are used to read the indu-
ration. A prior Bacillus Calmette-Gue´rin (BCG) vaccine may
influence the PPD reaction depending on conditions such as
the interval between BCG vaccination and TST and the age
at vaccination.21 If the prevalence of TB infection is high
enough, the positive predictive value of TST would be
higher.22 If the patient returns for a reading beyond 72
hours but before the 7th post-injection day, a positive test
can still be read. A repeat test may be needed if there is no
induration and the wheals present beyond the stipulated
time for reading. A repeat tuberculin test, when required,
should preferably be performed on the other arm.
3.3. Chest radiography
There are no pathognomonic radiological signs of TB. Chest
radiography merely localizes the site of pathology and does
not confirm etiology.23 In relevant clinical settings, certain
radiological lesions may strongly suggest TB. These lesions
include miliary, hilar, and paratracheal lymphadenopathywith or without parenchymal involvement and fibrocaseous
cavitatory lesions. In clinical practice, nonresolving chest
shadows following adequate antibiotic therapy in a symp-
tomatic child raise the possibility of TB. It is worth men-
tioning that not all persistent radiological lesions are
necessarily due to TB. Asymptomatic patients may have
persistent shadows due to parenchymal scarring, pleural
thickening, and healed fibroatelectatic changes. However,
a child with bronchiectasis or an interstitial lung disease
may present with nonresolving shadows with persistent
symptoms.
Ultrasonography of the chest is helpful to assess pleural
fluid collection, but a decubitus chest X-ray film may also
reveal similar information.23 High-resolution computed to-
mography (CT) offers excellent anatomical visualization,
and low-dose CT for children suspected of having pulmo-
nary TB infection can help in the decision to pursue further
antibiotic treatment.24 However, because of the high cost
of CT and the high level of radiation to which the patient is
exposed, as compared with other forms of imaging, it
should be reserved for complicated cases.25
3.4. Bacteriology
A confirmation of AFB from any body fluid or tissue is the
gold standard for the diagnosis of TB. Such proof is often
lacking in childhood TB cases because of the difficulty in
the collection of sputum and because of paucibacillary
primary disease in children. However, studies indicate that
the positive AFB test yield in advanced childhood cases may
be as high as that in adults. Several studies have reported
bacteriological positivity rates as high as 33% even for pri-
mary disease states, such as hilar adenopathy.26 Therefore,
every attempt must be made to bacteriologically prove the
diagnosis in every case of suspected TB. Early morning
gastric aspirate is the preferred specimen for most young
Childhood tuberculosis in Taiwan 299children with suspected TB. The aspirate is preferable for
both detecting AFB and isolating Mycobacterium tuber-
culosis.13 Whatever method a clinician uses, he/she needs
to collect at least two, preferably three, samples.
A Ziehl-Neelsen stain can reveal AFB only if the sample
contains greater than 10,000 bacilli per mL. Different cul-
ture methods, such as Lowenstein-Jensen medium, radio-
metric (Bactec 12B liquid medium), and nonradiometric
(Bactec MGIT 960 system), can be used for confirming
diagnosis in the paucibacillary state.27 The newer methods
are capable of providing faster results and may be used if
available. Mycobacterial culture assumes special signifi-
cance in cases of suspected drug resistance.27
Recent advances in bacteriological and molecular
methods to improve TB diagnosis have been described
recently. These methods include the microscopic observa-
tion drug susceptibility (MODS) test,28 more sensitive pul-
monary computed tomography (PCT) techniques,29 or
phage-based tests.30 However, although several studies on
diagnostic accuracy of these methods in adults were pub-
lished with considerably heterogeneous results, very few
data are available on children. In December 2010, the Xpert
MTB/RIF assay (“Xpert”, Cepheid Inc., Sunnyvale, CA, USA)
was endorsed by the WHO for direct TB screening on spu-
tum samples.31 The Xpert MTB/RIF assay is less sensitive
than liquid cultures for the detection of M. tuberculosis in
both children and adults; it provides results quickly, is
highly specific, and detects resistance to rifampin.31
3.5. Interferon Gamma Release Assays (IGRAs)
In addition to the traditional TST, which is known to lack
both sensitivity and specificity, blood-based assays have
recently become available. These T-cell assays rely on the
stimulation of host blood cells with M. tuberculosis-specific
antigens and measure the production of interferon g. Sev-
eral studies have compared the two available commercial
assays, T-Spot TB (Oxford Immunotec, Abingdon, UK) and
Quantiferon-TB Gold (Cellestis, Carnegie, Australia), with
the TST for both the detection of active disease and latent
TB infection.32 The T-cell assays have proven to be more
specific than the TST but are currently unable to distinguish
between active disease and latent TB infection.32 There-
fore, interpretation of the results remains dependent on
the clinical context. Several studies have presented pedi-
atric T-cell assay data; however, none have provided an
assessment of age-related performance, and reservations
remain regarding their performance in very young children
and immunocompromised populations, such as those with
HIV infection.33 The costs and technical demands of IGRAs
will most likely limit their wider use in resource-poor set-
tings where better tests are most needed.
3.6. PCR testing
Nucleic acid amplification tests using polymerase chain
reaction (PCR) cannot differentiate living bacilli from dead
bacilli. Thus, these tests continue to give positive results
even after successful treatment. The PCR tests are positive
in 95e100% of culture-positive cases and in 50e60% of
culture-negative cases.34 Over the past several decades,the diagnostic methods for M. tuberculosis have improved,
and nucleic acid amplification techniques now allow rapid
and sensitive detection in the clinical setting.35
4. Treatment of TB in Children
The principles of TB treatment are the same for adults and
children. The combination regimens used to treat active
disease aim to eliminate actively replicating and dormant
or near-dormant mycobacteria using a combination of
minimum-toxicity drugs with different actions while pre-
venting the emergence of drug-resistant organisms.36
TB treatment consists of two phases: an intensive phase
with a combination of bactericidal drugs to kill the rapidly
growing bacilli and a continuation phase with fewer drugs
to eradicate the slower-growing persistent bacilli.36 The
adjunctive use of steroids in TB meningitis has been shown
to reduce death and severe disability.37
Fixed-dose combination tablets contribute to increased
adherence to treatment regimens, but the marked differ-
ences in absorption, distribution, and excretion of phar-
macological agents in children of various ages might
require dose adjustments.38 Table 2 lists the regimens by
disease category as currently recommended by the
WHO,36,38 and Table 3 lists the regimens by disease cat-
egory as currently recommended by the Taiwan CDC.39 A
number of pharmacokinetic (PK) studies in children indi-
cate that age is a determinant of serum levels for all the
first-line anti-TB drugs and that infants and young children
have lower peak serum levels than older children or
adults.36,40,41 The revised recommended dosages are listed
in Table 4.
4.1. Drug-resistant TB
Poor patient compliance to anti-TB therapy is the major
contributory factor to the failure of a TB control program
and has increasingly led to drug resistance.38 The rates of
drug resistance to any drug vary from 20% to 80% in dif-
ferent geographic regions.38,42
Resistance should be suspected if an index case has
known resistant TB, if the child demonstrates initial
improvement on anti-TB treatment and then deteriorates,
or if there is no response to the initial treatment. Acquired
resistance is well described in HIV co-infected adults,
possibly resulting from a higher proportion of drug-resistant
strains in endemic areas, decreased absorption of oral
antimycobacterial drugs among HIV-infected persons, or
other factors.43 The presence of acquired resistance in the
pediatric population has also been reported; in particular,
children with HIV/TB co-infection should be closely
monitored.44
The current guidelines recommend using at least four
patient-naı¨ve drugs, including an injectable and a fluo-
roquinolone, in an initial phase for at least 6 months. The
initial phase should be followed by the use of at least three
of the most active and best-tolerated drugs in a 12e18
month continuation phase. Standardized regimens have
been developed for settings where drug susceptibility
testing is not available.45 Six classes of second-line drugs
are available, but research on the use of these drugs in
Table 2 Treatment regimens for children recommended by WHO.36,38
Category of treatment Category of TB cases Anti-TB drug regimens
Intensive phase Continuation phase
I New patient regimen 2HRZE 4HR
New smear-positive PTB
Smear-negative PTB with extensive
parenchymal involvement
Severe forms of EPTB other than TB
meningitis
II New patient regimen 2HRZ 4HR*
Smear-negative PTB without extensive
parenchymal involvement
Less severe forms of EPTB (e.g.,
TB cervical adenitis)
III New patient regimen 2HRZSy 4HR
TB meningitis
IV Retreatment regimen 2HRZES/1HRZE 5HRE
Previously treated smear-positive PTB
(relapse, treatment after interruption or
treatment failure)
If low risk for MDR-TB or risk unknown,
continue with retreatment regimen
If high risk for MDR-TB, use MDR-TB
regimen below
V MDR regimen Individualized regimens
MDR-TB
E Z ethambutol; EPTB Z extrapulmonary tuberculosis; H Z isoniazid; HIV Z human immunodeficiency virus; MDR-TB Z multidrug-
resistant tuberculosis; PTB Z pulmonary tuberculosis; R Z rifampicin; S Z streptomycin; Z Z pyrazinamide; WHO Z World Health
Organization.
* 2HRZ 4HR denotes a 2-month intensive phase of daily isoniazid, rifampicin, and pyrazinamide followed by a 4-month continuation
phase of daily isoniazid and rifampicin.
y Other regimens are recommended for treatment of TB meningitis that include replacing streptomycin with ethionamide and treating
for 9e12 months.
300 K.-S. Tsai et alchildren is limited, and multicenter pediatric trials are
needed.45 Under optimal circumstances, multidrug-
resistant TB responds well to appropriate therapy. Howev-
er, delays in diagnosis and treatment, adherence issues,Table 3 Treatment regimens for children recommended






PTB, mild EPTB 2HRZ 4HR*
Severe EPTB 2HRZ 7e10HR
TB meningitis 2HRZA or 2HRZP 7e10HR
MDR Individualized regimens
HIV infection 2HRZ 7e10HR
A Z aminoglycoside; EPTB Z extrapulmonary tuberculosis;
H Z isoniazid; HIV Z human immunodeficiency virus;
MDR Z multidrug resistance; P Z prothionamide;
PTB Z pulmonary tuberculosis; R Z rifampicin;
Z Z pyrazinamide.
* 2HRZ 4HR denotes a 2-month intensive phase of daily iso-
niazid, rifampicin, and pyrazinamide followed by a 4-month
continuation phase of daily isoniazid and rifampicin.and a lack of child-friendly formulations and strategies for
directly observed treatments (DOTS) frequently complicate
management and contribute to high morbidity and
mortality.46Table 4 First line anti-tuberculosis (TB) drugs for children
currently recommended by WHO36,38 and the Center for
Disease Control (CDC) Taiwan.39
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Several large-scale randomized clinical trials in different
settingsworldwide have suggested aprotective efficacy from
BCG vaccination against pulmonary TB that ranges from0% to
80%.47 The variability in vaccine efficacy has been attributed
to several factors, including strain-specific immunogenicity,
technique of vaccine administration, age at vaccination,
genetic differences between populations, host nutritional
factors, host co-infection by parasites, exposure to envi-
ronmental mycobacteria, and genetic variation in M. tuber-
culosis strains. However, the greatest effect of BCG
vaccination seems to be in preventing severe disseminated
disease in young children, includingTBmeningitis andmiliary
TB.47 The longevity of protection is less clear. A meta-
analysis of early trials suggested that protective immunity
lasts less than 10 years; however, more recent data suggest
that protection could persist for 50e60 years.48,49
The WHO guidelines recommend administration of BCG
soon after birth to all infants in countries with high TB
prevalence.50 To date, the efficacy of BCG vaccination has
not been determined in HIV-infected individuals in whom
the immune responses to the vaccine could be reduced,51
although this topic is the focus of ongoing trials. Because
of the risk of disseminated BCG disease that might com-
plicate the use of this live vaccine in immunocompromised
individuals, BCG vaccination is not recommended in chil-
dren known to be infected with HIV infection in low-TB
prevalence countries.50,51
Given the proven efficacy of the existing BCG vaccine in
preventing disseminated TB in children and reducing child
mortality, two conceptually different strategies are being
pursued.49 First, the development of priming vaccines,
which, it is hoped, will replace BCG by providing better and
longer-term protection. Second, researchers are pursuing
the design of booster vaccines to boost pre-existing BCG-
derived immunity. All of the novel vaccines currently under
development use a booster strategy following priming with
BCG in infancy. Such a vaccine could be used as a booster
vaccine with the goal of preventing new infections in those
uninfected with M. tuberculosis and to prevent reactivation
in those with latent TB infection.Acknowledgments
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